Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | FNTA | P49354 | 5/20 | 0.68 |
| ▸ | FNTB | P49356 | 5/20 | 0.68 |
| ▸ | SQLE | Q14534 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515165 | 1.00 | KMT2A (0.71) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL16451624 | 1.00 | KMT2A (0.71) | KMT2AFNTAFNTBSQLEMAPT | |
| Turbinaric Acid SCHEMBL2230248 | 1.00 | KMT2A (0.71) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL12104056 | 0.94 | KMT2A (0.63) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL20435504 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL458220 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL31652308 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL1952603 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL1395165 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT | |
| SCHEMBL5080365 | 0.91 | FNTA (0.72) | KMT2AFNTAFNTBSQLEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482509-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | Prospera Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161264-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | PROSPERA BIOTECH, S.L. (ES) | 2023-08-31 | — | — | WO | claimed |
| CN-110621654-B | TRPV1 modulator compounds | 安塔尔遗传学公司 | 2022-11-01 | — | — | CN | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20250161409-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | PROSPERA BIOTECH, S.L. (ES) | 2025-05-22 | — | — | US | disclosed |
| EP-4482509-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | Prospera Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-8044034-B2 | Nanoparticle derivatives of gemcitabine | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-10-25 | — | — | US | disclosed |
| EP-2055711-B1 | Use of squalenic acid for the formulation of an active principle in nanoparticle state | CENTRE NAT RECH SCIENT (FR) | 2011-08-17 | — | — | EP | disclosed |
| US-20100160249-A1 | NANOPARTICLE DERIVATIVES OF GEMCITABINE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7704972-B2 | Gemcitabine derivatives nanoparticles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090130214-A1 | Gemcitabine derivatives nanoparticles | Universite Paris-Saclay (FR) | 2009-05-21 | — | — | US | disclosed |
| EP-2055711-A1 | Use of squalenic acid for the formulation of an active principle in nanoparticle state | Centre National de la Recherche Scientifique (FR) | 2009-05-06 | — | — | EP | disclosed |
| EP-1925624-A1 | Use of squalenic acid for the formulation of an active principle in nanoparticle state | Centre National de la Recherche Scientifique (FR) | 2008-05-28 | — | — | EP | disclosed |
| EP-1761551-A1 | GEMCITABINE DERIVATIVES NANOPARTICLES | The Centre National de la Recherche Scientifique (FR) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006090029-A1 | GEMCITABINE DERIVATIVES NANOPARTICLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | KMT2A 1805/4885FNTA 4079/4885FNTB 3167/4885 |
| US-20250161409-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | TRPV1, NHERF1, SLC18A1 | KMT2A 4581/4885FNTA 4364/4885FNTB 4304/4885 |
| US-20100160249-A1 | NANOPARTICLE DERIVATIVES OF GEMCITABINE | SGMS1, GNA15, GNA11 | KMT2A 3662/4885FNTA 98/4885FNTB 553/4885 |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | KMT2A 2880/4885FNTA 2938/4885FNTB 2553/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | KMT2A 4217/4885FNTA 406/4885FNTB 1467/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KMT2A 1986/4885FNTA 1875/4885FNTB 1994/4885 |
| US-20090130214-A1 | Gemcitabine derivatives nanoparticles | KRAS, H1-3, MCL1 | KMT2A 1253/4885FNTA 2157/4885FNTB 3146/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | KMT2A 1618/4885FNTA 1228/4885FNTB 2155/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | KMT2A 3504/4885FNTA 3478/4885FNTB 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.